Analysis of ADGRF5 expression in CRC patients according to tumor-node-metastasis (TNM) staging system revealed higher expression of ADGRF5 when the extent of the tumors was classified as a T3 and T4 compared to the tumors described as a T1 and T2 (p < 0.01). This evidence concerns the gene ADGRF5 and colorectal carcinoma.